A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
Price : $35 *
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Dynavax Technologies
- 23 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 08 Dec 2013 New trial record